Business Standard

Monday, December 23, 2024 | 09:41 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Best of BS Opinion: Covaxin gets a booster, pandemic risk in IPOs, and more

Here are the best of BS Opinion pieces of the day

Covaxin has started trials on children; it would be for children who are two years or older
Premium

Kanika Datta
After a long delay, the World Health Organization has approved the Indian-manufactured vaccine Covaxin for emergency use. Scaling this hurdle – finally -- raises key questions about the next steps in the Covid-19 vaccination programme. The top edit outlines the key issues here

In other views:

The prime minister’s Panchamrita pledge at Glasgow burnishes India’s climate credentials, but a perilous future awaits the world. Shyam Saran discusses what’s at stake.  Read it here

The second edit explains how the renaming of Facebook will help the social media giant in multiple ways. Read it here

Covid-19

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in